Amphista Therapeutics, a United Kingdom-based biopharmaceutical company, has named Dr Ian Churcher as its chief scientific officer, it was reported on Thursday.
Dr Churcher has headed the Protein Degradation Discovery Performance Unit at GSK and also led teams developing drug discovery technologies and advancing medicines across multiple therapy areas during an R&D career at Merck and GSK. He also headed research at biotechnology companies including as SVP Drug Discovery at BenevolentAI.
Amphista's CEO, Dr Nicola Thompson, said, 'I'm delighted to welcome Ian to the team. As an internationally recognised leader in the field of targeted protein degradation (TPD) as a therapeutic modality, Ian's scientific leadership will be a tremendous addition to the Amphista team as we progress our TPD pipeline to the clinic. Ian's appointment so soon after last month's USD7.5m Series A financing signals Amphista's determination to deliver on its vision to create a world-leading protein degradation company delivering ground-breaking new medicines in areas of high patient need.'
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business